About: http://hub.abes.fr/edp/periodical/medsci/2023/volume_39/issue_67/msc230100/w

Documentation

scienceplus.abes.fr version Bêta

scienceplus.abes.fr | explorer

À propos de : http://hub.abes.fr/edp/periodical/medsci/2023/volume_39/issue_67/msc230100/w Goto Sponge NotDistinct Permalink

Attributs	Valeurs
type	work Article
Is Part Of	http://hub.abes.fr/edp/periodical/medsci/2023/volume_39/issue_67/w
Subject	Forum
subtitle	Chroniques génomiques
License	https://creativecommons.org/licenses/by/4.0
Title	Nouveau et (beaucoup) plus cher - Meilleur ?
Date	2023-01-01(xsd:dateTime)
has manifestation of work	http://hub.abes.fr/edp/periodical/medsci/2023/volume_39/issue_67/msc230100/m/print http://hub.abes.fr/edp/periodical/medsci/2023/volume_39/issue_67/msc230100/m/web
related by	http://hub.abes.fr/edp/periodical/medsci/2023/volume_39/issue_67/msc230100/authorship/1
Author	Jordan, Bertrand Jordan, Bertrand
Abstract	The prices of new oncology drugs are frequently above 100,000 US dollars, and this does not generally correlate with significantly improved clinical efficacy. In the absence of effective regulation and of real competition, companies tend to charge « what the market can bear ». Regulatory intervention is required, notably at the EU level.
article type	research-article
publisher identifier	msc230100
Date Copyrighted	2023-01-01(xsd:dateTime)
Rights	© 2023 médecine/sciences - Inserm
Rights Holder	médecine/sciences - Inserm
is part of this journal	médecine/sciences
is primary topic of	http://hub.abes.fr/edp/periodical/medsci/2023/volume_39/issue_67/msc230100/w/record

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata